PI & SITE INTEREST FORM
Rapid-Acting Treatments for Neuropsychiatric Diseases
See latest data
a rapid-acting neuroplastogen
We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked.
The Latest From Transcend
Transcend Therapeutics announces publication of new preclinical data demonstrating TSND-201 (methylone) is a rapid-acting neuroplastogen with fewer off-target effects than MDMA
Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA
Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data
TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)
Striving for a world without neuropsychiatric disease.
Because 1 billion patients
Help us bring new mental health solutions to patients
Join us in creating a world free from neuropsychiatric disease.